Poorly Differentiated Chordoma: Case Review
N. V. Kochergina,
I. V. Boulytcheva,
S. N. Prokhorov,
A. B. Bludov,
A. V. Fеdorova,
O. G. Spirina,
Ya. A. Shсhipakhina https://doi.org/10.37174/2587-7593-2020-3-4-86-93
Abstract
Purpose: Demonstrate a clinical case of poorly differentiated chordoma, confirmed using a wide range of research methods.
Material and methods: A 63-year-old female patient with poorly differentiated chordoma who underwent immunohistochemical examination, MRI, CT and scintigraphy.
Results: An immunohistochemical study confirmed the morphological affiliation of the tumor, supplemented by the data of imaging methods.
Conclusion: The poorly differentiated type of chordoma has a specific immunohistochemical picture, however, differential diagnosis based on imaging methods is currently a difficult task.
About the Authors
N. V. Kochergina
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
24 Kashirskoye Highway, Moscow, 115478
Russian Federation
24 Kashirskoye Highway, Moscow, 115478
I. V. Boulytcheva
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
24 Kashirskoye Highway, Moscow, 115478
Russian Federation
24 Kashirskoye Highway, Moscow, 115478
S. N. Prokhorov
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
24 Kashirskoye Highway, Moscow, 115478
Russian Federation
24 Kashirskoye Highway, Moscow, 115478
A. B. Bludov
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
24 Kashirskoye Highway, Moscow, 115478
Russian Federation
24 Kashirskoye Highway, Moscow, 115478
A. V. Fеdorova
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
24 Kashirskoye Highway, Moscow, 115478
Russian Federation
24 Kashirskoye Highway, Moscow, 115478
O. G. Spirina
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
24 Kashirskoye Highway, Moscow, 115478
Russian Federation
24 Kashirskoye Highway, Moscow, 115478
Ya. A. Shсhipakhina
N.N. Blokhin National Medical Research Center of Oncology
Russian Federation
24 Kashirskoye Highway, Moscow, 115478
Russian Federation
24 Kashirskoye Highway, Moscow, 115478
References
1. Murphey MD, Andrews CL, Flemming DJ, et al. From the archives of the AFIP. Primary tumors of the spine: radiologic pathologic correlation. Radiographics. 1996;16 (5): 1131-58. DOI: 10.1148/radio-graphics.16.5.8888395.
2. McMaster ML, Goldstein AM, Bromley CM, et al. Chordoma: incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control. 2001;12:1-11. DOI: 10.1023/a:1008947301735.
3. Wold LE, Laws ER Jr. Cranial chordomas in children and young adults. J Neurosurg. 1983;59:1043-7. DOI: 10.3171/jns.1983.59.6.1043.
4. Fletcher CDM, Bridge JA, Hogendoorn PCW, et al eds. WHO Classification of Tumours of Soft Tissue and Bone Geneva: WHO Press; 2013.
5. Vujovic S, Henderson S, Presneau N, et al. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol. 2006;209:157-65. DOI: 10.1002/path.1969.
6. Hasselblatt M, Thomas C, Hovestadt V, et al. Poorly differentiated chordoma with SMARCB1/INI1 loss: a distinct molecular entity with dismal prognosis. Acta Neuropathol. 2016;132:149-51. DOI: 10.1007/s00401-016-1574-9.
7. Hoch BL, Nielsen GP, Liebsch NJ, et al. Base of skull chordomas in children and adoles-cents: a clinicopathologic study of 73 cases. Am J Surg Pathol. 2006;30:811-8. DOI: 10.1097/01.pas.0000209828.39477.ab.
8. Mobley BC, McKenney JK, Bangs CD, et al. Loss of SMARCB1/INI1 expression in poorly differentiated chordomas. Acta Neuropathol. 2010;120:745-53. DOI: 10.1007/s00401-010-0767-x.
9. Shih AR, Cote GM, Chebib I, et al. Clinicopathologic characteristics of poorly differentiated chordoma. 2018 DOI: 10.1038/s41379-018-0002-1.
10. Azzarelli A, Quagliuolo V, Cerasoli S, et al. Chordoma: natural history and treatment results in 33 cases. J Surg Oncol. 1988;37:185-91. DOI: 10.1002/jso.2930370311.
11. Patel SS, Schwab JH. Immunotherapy as a potential treatment for chordoma: a review. Curr Oncol Rep. 2016;18:55. DOI: 10.1007/s11912-016-0543-8.
12. Stacchiotti S, Casali PG. Systemic therapy options for unresectable and metastatic chordomas. Curr Oncol Rep. 2011;13:323-30 DOI: 10.1007/s11912-011-0176-x.
13. Stacchiotti S, Longhi A, Ferraresi V, et al. Phase II study of imatinib in advanced chordoma. J Clin Oncol. 2012;30:914-20. DOI: 10.1200/JCO.2011.35.3656.
14. Stacchiotti S, Tamborini E, Lo Vullo S, et al. Phase II study on lapatinib in advanced EGFR-positive chordoma. Ann Oncol. 2013;24:1931-6. DOI: 10.1093/annonc/mdt117.
15. Al-Rahawan MM, Siebert JD, Mitchell CS, et al. Durable complete response to chemotherapy in an infant with a clival chordoma. Pediatr Blood Cancer. 2012;59:323-5. DOI: 10.1002/pbc.23297.
16. Scimeca PG, James-Herry AG, Black KS, et al. Chemotherapeutic treatment of malignant chordoma in children. J Pediatr Hematol Oncol. 1996;18:237-40. DOI: 10.1097/00043426-199605000-00032.
17. Wilson BG, Wang X, Shen X, et al. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell. 2010;18:316-28. DOI: 10.1016/j.ccr.2010.09.006.
18. Shih AR, Chebib I, et al. Molecular characteristics of poorly differentiated chordoma. Genes chromosomes and cancer. 2019; 58:804-808. DOI: 10.1002/gcc.22782.
19. Yeom KW, Lober RM, Mobley BC, et al. Diffusion-weighted MRI: distinction of skull base chordoma from chondrosarcoma. Am J Neuroradiol. 2013;34(5):1056-61. DOI: 10.3174/ajnr.A3333.
Review
For citations:
Kochergina N.V., Boulytcheva I.V., Prokhorov S.N., Bludov A.B., Fеdorova A.V., Spirina O.G., Shсhipakhina Ya.A. Poorly Differentiated Chordoma: Case Review. Journal of oncology: diagnostic radiology and radiotherapy. 2020;3(4):86-93. (In Russ.) https://doi.org/10.37174/2587-7593-2020-3-4-86-93
Views:
572
Email this article 